帕博利珠单抗联合卡铂和多西他赛新辅助治疗三阴性乳腺癌的临床与生物标志物发现:NeoPACT 2期临床试验
这项开放标签2期试验在2个中心入组115例I至III期三阴性乳腺癌女性患者,接受6周期卡铂(游离卡铂血浆浓度-时间曲线下面积为6)和多西他赛(75 mg/m2)联合帕博利珠单抗(200 mg)每21天一次的新辅助治疗。病理完全缓解率为58%(95%CI,48%-67%),残余肿瘤负荷0+1率为69%(95%CI,60%-78%),3年无事件生存率全体为86%、pCR组为98%、未达pCR组为68%。
要点
- 6周期卡铂+多西他赛+帕博利珠单抗新辅助方案的pCR率为58%(95%CI,48%-67%)。
- 3级及以上免疫相关不良事件发生率为3.5%。
- sTILs、PD-L1、DDIR和TIM在多变量分析中均独立预测pCR。
核心结论
- 2期试验结果表明,新辅助卡铂和多西他赛联合帕博利珠单抗显示出令人鼓舞的pCR和3年EFS。
- 该方案耐受性良好,多种生物标志物识别的免疫富集独立预测pCR。
- 这些结果为不适合蒽环类方案的患者提供了免蒽环类化学免疫治疗方案的替代数据,并支持在随机研究中进一步评估该方案作为三阴性乳腺癌化疗降阶梯策略。
研究设计与样本
- 开放标签2期临床试验,单组设计,入组I至III期三阴性乳腺癌患者,来自2个中心。
- 患者接受新辅助卡铂(游离卡铂血浆浓度-时间曲线下面积为6)和多西他赛(75 mg/m2)联合帕博利珠单抗(200 mg)每21天一次,共6周期,所有周期均给予髓系生长因子支持。
- 符合条件的研究人群为115例女性患者(中位[范围]年龄,50[27-70]岁),入组时间为2018年9月至2022年1月,39%有淋巴结阳性疾病。
- 主要终点为病理完全缓解(pCR),定义为乳腺和腋窝无浸润性肿瘤证据;次要终点包括残余肿瘤负荷、EFS、毒性和免疫生物标志物。
主要发现
- pCR率为58%(95%CI,48%-67%),残余肿瘤负荷0+1率为69%(95%CI,60%-78%)。
- 3级及以上免疫介导不良事件发生于3.5%的患者。
- sTILs、PD-L1、DDIR和TIM在多变量分析中均预测pCR,pCR的曲线下面积分别为sTILs 0.719、PD-L1 0.740、DDIR 0.699、TIM 0.715。
- 估计3年EFS在全体患者中为86%,pCR组为98%,无pCR组为68%。
临床怎么用
- 原文结论指出,这些结果为不适合蒽环类方案的患者提供了免蒽环类化学免疫治疗方案的数据,并支持在随机研究中进一步评估该方案作为三阴性乳腺癌化疗降阶梯策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Addition of pembrolizumab to anthracycline-based chemotherapy improves pathologic complete response (pCR) and event-free survival (EFS) in triple-negative breast cancer (TNBC). The efficacy of anthracycline-free chemoimmunotherapy in TNBC has not been assessed. OBJECTIVE: To assess the efficacy of the anthracycline-free neoadjuvant regimen of carboplatin and docetaxel plus pembrolizumab in TNBC. DESIGN, SETTING, AND PARTICIPANTS: This was an open-label phase 2 clinical trial including a single group of patients with stage I to III TNBC enrolled at 2 sites who received neoadjuvant carboplatin and docetaxel plus pembrolizumab every 21 days for 6 cycles. Participants were enrolled from 2018 to 2022. INTERVENTION OR EXPOSURE: Carboplatin (with an area under the free carboplatin plasma concentration vs time curve of 6) and docetaxel (75 mg/m2) plus pembrolizumab (200 mg) every 21 days for 6 cycles. Myeloid growth factor support was administered with all cycles. MAIN OUTCOMES AND MEASURES: Primary end point was pathologic complete response (pCR) defined as no evidence of invasive tumor in breast and axilla. The secondary end points were residual cancer burden, EFS, toxicity, and immune biomarkers. RNA isolated from pretreatment tumor tissue was subjected to next-generation sequencing. Specimens were classified as positive or negative for the 44-gene DNA damage immune response (DDIR) signature and for the 27-gene tumor immune microenvironment (TIM; DetermaIO) signature using predefined cutoffs. Stromal tumor-infiltrating lymphocytes (sTILs) were evaluated using standard criteria. Programmed cell death-ligand 1 (PD-L1) testing was performed using a standard immunohistochemical assay. RESULTS: Among the eligible study population of 115 female patients (median [range] age, 50 [27-70] years) who enrolled from September 2018 to January 2022, 39% had node-positive disease. pCR and residual cancer burden 0 + 1 rates were 58% (95% CI, 48%-67%) and 69% (95% CI, 60%-78%), respectively. Grade 3 or higher immune-mediated adverse events were observed in 3.5% of patients. sTILs, PD-L1, DDIR, and TIM were each predictive of pCR in multivariable analyses. The areas under curve for pCR were 0.719, 0.740, 0.699, and 0.715 for sTILs, PD-L1, DDIR, and TIM, respectively. Estimated 3-year EFS was 86% in all patients; 98% in pCR group and 68% in no-pCR group. CONCLUSIONS AND RELEVANCE: The findings of the phase 2 clinical trial indicate that neoadjuvant carboplatin and docetaxel plus pembrolizumab shows encouraging pCR and 3-year EFS. The regimen was well tolerated, and immune enrichment as identified by various biomarkers was independently predictive of pCR. These results provide data on an alternative anthracycline-free chemoimmunotherapy regimen for patients who are not eligible for anthracycline-based regimens and support further evaluation of this regimen as a chemotherapy de-escalation strategy in randomized studies for TNBC. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03639948.
引用
- Sharma P, Stecklein SR, Yoder R, et al. Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial. JAMA Oncol. 2024. PMID: 37991778. doi:10.1001/jamaoncol.2023.5033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。